1. Capecitabine monotherapy as first-line treatment in advanced HER2-normal breast cancer - a nationwide, retrospective study.
- Author
-
Celik A, Berg T, Gibson M, Jensen MB, Kümler I, Eßer-Naumann S, Jakobsen EH, Knoop A, and Nielsen D
- Subjects
- Humans, Female, Retrospective Studies, Middle Aged, Aged, Adult, Antimetabolites, Antineoplastic therapeutic use, Aged, 80 and over, Denmark, Progression-Free Survival, Receptors, Estrogen metabolism, Capecitabine therapeutic use, Capecitabine administration & dosage, Breast Neoplasms drug therapy, Breast Neoplasms mortality, Breast Neoplasms pathology, Receptor, ErbB-2 metabolism
- Abstract
Background and purpose: Capecitabine can be used as first-line treatment for advanced breast cancer. However, real-world data on efficacy of capecitabine in this setting is sparse. The purpose of the study is to evaluate outcomes of patients with Human Epidermal Growth Factor Receptor (HER2)-normal advanced breast cancer treated with capecitabine monotherapy as first-line treatment., Material and Methods: The study utilized the Danish Breast Cancer Group (DBCG) database and was conducted retrospectively across all Danish oncology departments. Inclusion criteria were female patients, with HER2-normal advanced breast cancer treated with capecitabine monotherapy as the first-line treatment from 2010 to 2020. The primary endpoints were overall survival (OS) and progression-free survival (PFS)., Results: A total of 494 patients were included. Median OS was 16.4 months (95% confidence interval [CI]: 14.5-18.0), and median PFS was 6.0 months (95% CI: 5.3-6.7). Patients with estrogen receptor (ER)-positive disease had significantly longer OS (median: 22.8 vs. 10.5 months, p < 0.001) and PFS (median: 7.4 vs. 4.9 months, p = 0.003), when compared to ER-negative patients. Stratifying by age, patients under 45 years displayed a median PFS of 4.1 months, while those aged 45-70 years and over 70 years had median PFS of 5.7 and 7.2 months, respectively (p = 0.01)., Interpretation: In this nationwide study, the efficacy of capecitabine as a first-line treatment for HER2-normal advanced breast cancer is consistent with other, mainly retrospective, studies. However, when assessed against contemporary and newer treatments, its effectiveness appears inferior to alternative chemotherapies or targeted therapies.
- Published
- 2024
- Full Text
- View/download PDF